Related Experiment Video

Updated: Nov 5, 2025

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.7K

Druggability of lipid metabolism modulation against renal fibrosis

Yuan-Yuan Chen1, Xiao-Guang Chen2, Sen Zhang3

  • 1State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union medical college, Beijing, 100050, China.

Acta Pharmacologica Sinica
|May 15, 2021
PubMed

Insights

Targeting kidney lipid metabolism offers a new strategy for treating renal fibrosis, a common cause of kidney failure. Restoring fatty acid oxidation and reprogramming lipid metabolism show promise for developing effective anti-fibrotic therapies.

Area of Science:

  • Nephrology
  • Metabolic Research
  • Pharmacology

Background:

  • Renal fibrosis is a key factor in chronic kidney disease progression and kidney failure, lacking effective treatments.
  • Lipid accumulation and lipotoxicity are common in chronic kidney disease and fibrosis.
  • Restoring impaired fatty acid oxidation in kidney cells can mitigate renal fibrosis.

Purpose of the Study:

  • To review the potential of targeting lipid metabolism for renal fibrosis treatment.
  • To highlight druggable targets and metabolic regulators with anti-fibrotic roles.
  • To discuss noncoding RNAs as novel drug targets for renal fibrosis via lipid metabolism.

Main Methods:

  • Literature review of pre-clinical evidence on lipid metabolism and renal fibrosis.
  • Identification of representative druggable targets and metabolic regulators.
  • Exploration of noncoding RNAs in the context of lipid metabolism and fibrosis.

Main Results:

  • Lipid metabolism reprogramming is a viable strategy for ameliorating renal fibrosis.
  • Several druggable targets and metabolic regulators demonstrate anti-fibrotic effects.
  • Noncoding RNAs present promising, yet preliminary, therapeutic potential.

Conclusions:

  • Targeting lipid metabolism, including noncoding RNAs, holds significant therapeutic promise for renal fibrosis.
  • Further research is needed to overcome deficiencies and advance drug development for targeting lipid reprogramming in the kidney.
Keywords:
anti-renal fibrosisdrug targetsfatty acid oxidationlipid metabolismnoncoding RNA

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

633
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

987

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
55
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
55
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
218
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
46
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.2K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K